Xenetic has developed a number of proprietary patented technologies that are being used to create a new generation of drug and vaccine products with improved performance. Xenetic’s technologies include:
PolyXen® for protein drug delivery
PolyXen® is a versatile enabling technology that uses the biopolymer polysialic acid to prolong the active life and improve the pharmacokinetics and pharmacodynamics of therapeutic peptides and proteins, as well as conventional small molecule drugs. PolyXen® is a next generation method to PEGylation for the delivery of protein drugs.
ImuXen® is an advanced enabling technology that uses liposome-based constructs to boost the effectiveness of DNA, protein and polysaccharide vaccines. ImuXen® can achieve protective immunity in a single dose.
Oncohist (recombinant human Histone H 1.3) is a novel biotherapeutic molecule for the treatment of tumours, in particular, haematologic malignancies. Histone H1 molecules have evolved to recognise and destabilise the membranes of tumour cells and micro-organisms displaying aberrant membrane characteristics. Oncohist has the same properties as the body's own histone H1 molecules. Oncohist has superior advantages over conventional cancer therapeutics, including high selectivity, low inherent toxicity, lack of induction of resistance and low immunogenicity.
